| Code | CSB-RA012871MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of mibavademab (REGN4461), targeting LEPR (leptin receptor; also known as OB-R / CD295), a type I cytokine receptor that mediates leptin signaling to regulate appetite, energy expenditure, and systemic metabolic homeostasis. Canonical LEPR signaling—particularly via the long signaling isoform (LepRb)—engages JAK2–STAT3 as a central axis, with additional downstream pathways shaping neuroendocrine and metabolic responses.
Mibavademab is described as an investigational leptin receptor agonist monoclonal antibody, designed to bind membrane LEPR and activate the receptor (i.e., a leptin-mimetic approach). This biosimilar enables researchers to investigate LEPR pathway biology—including receptor engagement/activation, downstream STAT3-driven transcriptional programs, and functional readouts relevant to metabolic regulation—independent of endogenous leptin variability. It supports assay development and mechanistic studies in settings where leptin–LEPR signaling is perturbed (e.g., leptin resistance or leptin/LEPR-axis disorders), providing a consistent antibody reagent for probing LEPR agonism in controlled experimental systems.
There are currently no reviews for this product.